Plasma from atherosclerotic patients exerts an increased degradation of platelet-activating factor.

No abstract is available for this paper.

• Publication year

  1987

• Venue

  Thrombosis Research

• Publication date

  1987-08-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/0049-3848(87)90141-1PMID 3629555
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Platelet activating factor: a biologically active phosphoglyceride.

  1986cited by this paper
• Platelet activating factor and inflammation in atherogenesis: Targets for drug development

  1986cited by this paper
• The role of lipoproteins in the degradation of platelet-activating factor.

  1986cited by this paper
• The degradation of platelet-activating factor in the plasma of a patient with familial high density lipoprotein deficiency (Tangier disease).

  1985cited by this paper
• Chemical and biochemical aspects of platelet activating factor: A novel class of acetylated ether‐linked choline‐phospholipids

  1985cited by this paper
• PAF-acether-induced release of tissue-type plasminogen activator from vessel walls.

  1985cited by this paper
• Inactivation of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine by a plasma acetylhydrolase: higher activities in hypertensive rats.

  1983cited by this paper
• CHAPTER 18 – Platelet-Activating Factor: An Ether Lipid with Biological Activity

  1983cited by this paper
• Human serum acid-labile factor is an acylhydrolase that inactivates platelet-activating factor.

  1983cited by this paper
• Metabolism of platelet-activating factor by blood platelets and plasma

  1983cited by this paper
• A specific acetylhydrolase for 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (a hypotensive and platelet-activating lipid).

  1981cited by this paper

• Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2

  2012cites this paper
• Thematic Review Series: New Lipid and Lipoprotein Targets for the Treatment of Cardiometabolic Diseases Modulation of oxidative stress, infl ammation, and atherosclerosis by lipoprotein-associated phospholipase A 2

  2012cites this paper
• Inflammatory Markers and Genes: Epidemiologic Studies on their Roles in Cardiovascular Disease

  2007influential citation
• Metabolism of the Proinflammatory Autacoid, Platelet-Activating Factor

  2005cites this paper
• Plasma platelet activating factor-acetylhydrolase (PAF-AH).

  2003cites this paper
• Lp-PLA2: an emerging biomarker of coronary heart disease

  2002cites this paper
• The Effect of 3‐Month Ingestion of Ginkgo biloba Extract (EGb 761) on Pancreatic β‐Cell Function in Response to Glucose Loading in Individuals with Non‐Insulin‐Dependent Diabetes Mellitus

  2001cites this paper
• Inhibition of lipoprotein‐associated phospholipase A2 diminishes the death‐inducing effects of oxidised LDL on human monocyte‐macrophages

  2001cites this paper
• The Effect of 3‐Month Ingestion of Ginkgo biloba Extract on Pancreatic β‐Cell Function in Response to Glucose Loading in Normal Glucose Tolerant Individuals

  2000cites this paper
• Plasma platelet-activating factor acetylhydrolase deficiency is associated with atherosclerotic occlusive disease in japan.

  2000cites this paper
• Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease

  2000cites this paper
• Spectrophotometric assay for serum platelet-activating factor acetylhydrolase activity.

  2000cites this paper
• Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease.

  2000cites this paper
• Correlations between plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and PAF-AH genotype, age, and atherosclerosis in a Japanese population.

  2000cites this paper
• Plasma and Lp(a)-associated PAF-acetylhydrolase activity in uremic patients undergoing different dialysis procedures.

  1999cites this paper
• Urinary platelet-activating factor excretion is elevated in non-insulin dependent diabetes mellitus.

  1999cites this paper
• Regulation of platelet-activating factor (PAF) activity in human diseases by phospholipase A2 inhibitors, PAF acetylhydrolases, PAF receptor antagonists and free radical scavengers.

  1999cites this paper
• Plasma platelet-activating factor acetylhydrolase activity in human immunodeficiency virus infection and the acquired immunodeficiency syndrome.

  1999cites this paper
• Estrogen effects on platelet-activating factor and platelet-activating factor acetylhydrolase activity in rat uterus during the late stages of pregnancy.

  1999cites this paper
• Roles of plasma platelet-activating factor acetylhydrolase in allergic, inflammatory, and atherosclerotic diseases.

  1998cites this paper
• Plasma PAF acetylhydrolase in non-insulin dependent diabetes mellitus and obesity: effect of hyperinsulinemia and lovastatin treatment.

  1997cites this paper
• Platelet-Activating Factor: Biosynthesis, Biodegradation, Actions

  1997cites this paper
• Impact of genomics on diagnostic medicine

  1997cites this paper
• Platelet-activating factor (PAF) and PAF acetylhydrolase activity in rat uterus and placenta during the late stages of pregnancy.

  1997cites this paper
• Purification, properties, sequencing, and cloning of a lipoprotein-associated, serine-dependent phospholipase involved in the oxidative modification of low-density lipoproteins.

  1996cites this paper
• The fate of platelet-activating factor: PAF acetylhydrolases from plasma and tissues

  1996cites this paper
• Mammalian platelet-activating factor acetylhydrolases.

  1996cites this paper
• Stimulation of platelet-activating factor synthesis in polymorphonuclear leukocytes from streptozotocin-induced diabetic rats.

  1995cites this paper
• Influence of a cigarette smoke extract on the hormonal regulation of platelet-activating factor acetylhydrolase in rats.

  1995cites this paper
• Platelet aggregability to platelet activating factor at rest and after exercise in patients with coronary artery disease.

  1995cites this paper
• Platelet‐activating factor: a mediator for clinicians

  1995cites this paper
• Platelet-activating factor (PAF): implications for coronary heart and vascular diseases.

  1994cites this paper
• Plasma degradation of platelet‐activating factor in severely ill patients with clinical sepsis

  1994cites this paper
• PAF and hematopoiesis. II. Elevated levels of plasma paf acetylhydrolase after rapid infusion of 5-fluorouracil in cancer patients.

  1994cites this paper
• Differentiation induced increase of platelet-activating factor acetylhydrolase in HL-60 cells.

  1994cites this paper
• High-density lipoprotein inhibits the production of platelet activating factor acetylhydrolase by HepG2 cells.

  1994cites this paper
• Generation of reactive oxygen species and activity of platelet-activating factor acetylhydrolase in human monocyte-derived macrophages.

  1994cites this paper
• Platelet-activating factor acetylhydrolase in the male reproductive tract: origin and properties.

  1993cites this paper
• Corneal PAF acetylhydrolase increases in anterior segment ischemia in rabbits.

  1993cites this paper
• Human platelets release a paf-acether: Acetylhydrolase similar to that in plasma

  1993cites this paper
• Variation in plasma platelet‐activating factor degradation and serum lipids after acute myocardial infarction

  1993cites this paper
• Effect of 17 beta-estradiol on secretion of platelet-activating factor acetylhydrolase by HepG2 cells.

  1993cites this paper
• Plasma platelet activating factor degradation and serum lipids after coronary bypass surgery.

  1992cites this paper
• Effect of a cigarette smoke extract on the metabolism of the proinflammatory autacoid, platelet-activating factor.

  1992cites this paper
• Paf-acether acetylhydrolase activity is increased in patients with rheumatic diseases.

  1992cites this paper
• Plasma platelet-activating factor degradation in patients with severe coronary artery disease.

  1992cites this paper
• PAF acetylhydrolase activities in human systemic lupus erythematosus and lupus-prone mice.

  1992cites this paper
• Platelet-activating factor and its metabolic effects.

  1991cites this paper
• Platelet-activating factor acetylhydrolase in plasma lipoproteins of healthy men and women.

  1991cites this paper
• PAF-acetylhydrolase, predominantly present in LDL in healthy subjects, is associated with HDL in a patient with LDL deficiency.

  1991cites this paper
• Platelet-activating factor (PAF) stimulates the production of PAF acetylhydrolase by the human hepatoma cell line, HepG2.

  1991cites this paper
• Liver cells secrete the plasma form of platelet-activating factor acetylhydrolase.

  1991cites this paper
• Platelet-activating factor.

  1990cites this paper
• A Plasmatic Factor May Cause Platelet Activation in Acute Ischemic Stroke

  1989cites this paper
• Enhanced degradation of platelet-activating factor in serum from diabetic patients.

  1989cites this paper
• 喫煙常習者における血漿platelet-activating factor (PAF) acetylhydrolaseとリポ蛋白

  1989cites this paper
• Blood Platelet Behaviour in Patients with a Type I Diabetes Mellitus

  1989cites this paper
• Increased activity of the platelet-activating factor acetylhydrolase in plasma low density lipoprotein from patients with essential hypertension.

  1989cites this paper
• The degradation of platelet-activating factor in serum and its discriminative value in atherosclerotic patients.

  1988cites this paper
• THE DBGRADATIOB OF PLATELET-ACTIVATIRG FACTOR IB SERUM ARD ITS DISCRIWIBATIVB VALUE IR ATHEROSCLEROTIC PATIEBTS

  1988cites this paper
• Characterization of serum platelet-activating factor (PAF) acetylhydrolase. Correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic children.

  1988cites this paper